Use of Cytohesin Inhibitors for Chemically Inducing Longevity

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes the use of specific compounds known as cytohesin inhibitors to pharmacologically induce increased longevity and to treat or prevent diseases related to the regulation of insulin and insulin-like growth factor (IGF) signaling pathways. The compounds, including various novel 1,2,4-triazole derivatives, act by inhibiting cytohesins, which modulate these signaling pathways. The inhibition can result in reduced insulin signaling, creating a state akin to insulin resistance, which experiments showed could extend lifespan in animals (such as flies) and may activate the immune system. These compounds may be administered orally or intravenously for therapeutic and preventive purposes.

Use CasesContent extracted from patent full text and abstract with AI.

• Pharmaceuticals for extending human or animal lifespan (anti-aging drugs)
• Therapeutic treatment for diseases associated with excessive insulin/IGF signaling, such as obesity, metabolic syndrome, and certain age-related organ pathologies (e.g., in liver or pancreas)
• Preventive medication for cellular aging and damage related to age
• Compounds for enhancing immune activation in specific contexts
• Prophylactic treatment to reduce risk of metabolic disorders or age-related diseases

BenefitsContent extracted from patent full text and abstract with AI.

• Chemical (non-genetic, non-surgical) induction of longevity, which could be widely adopted
• Ability to both treat and prevent age-related cellular and metabolic diseases
• May reduce incidence of obesity and associated chronic diseases
• Potential for low toxicity and suitability for long-term use
• Oral dosing is feasible, improving accessibility and compliance
• Possible positive effects on the immune system
• Versatility for both human and veterinary applications

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to compounds selected from among the group comprising general formulas (1), (2), (3), and/or (4) and/or the enantiomers, diastereomers, and derivatives thereof, and the pharmaceutically acceptable salts thereof for producing a medicament used for therapeutically and/or preventively treating diseases and pathological conditions linked to regulation of the insulin and/or insulin-like growth factor (IGF) signaling pathway and/or for chemically inducing longevity.